# Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

> **NCT01015833** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 356 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma
- Recurrent Hepatocellular Carcinoma
- Stage III Hepatocellular Carcinoma AJCC v7
- Stage IIIA Hepatocellular Carcinoma AJCC v7
- Stage IIIB Hepatocellular Carcinoma AJCC v7
- Stage IIIC Hepatocellular Carcinoma AJCC v7
- Stage IV Hepatocellular Carcinoma AJCC v7
- Stage IVA Hepatocellular Carcinoma AJCC v7
- Stage IVB Hepatocellular Carcinoma AJCC v7
- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacogenomic Study
- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT01015833
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-15
- **Primary completion:** 2015-05-21
- **Final completion:** 2018-08-15
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01015833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01015833, "Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01015833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*